Amgen’s updated Phase II data for MariTide in obesity may not have been the results the firm was looking for, but Amgen is trying to assure investors that based on learnings from an ongoing Phase II trial and a Phase I pharmacokinetic study, it knows the right approach in Phase III to improve the bispecific GLP-1 agonist/GIP receptor antagonist antibody’s gastrointestinal tolerability without sacrificing efficacy.
Key Takeaways
- Amgen updated the field on its Phase II bispecific antibody for obesity, showing 52-week data that analysts called competitive but with troubling tolerability findings.
The just-concluded American Diabetes Association annual meeting provided a platform for several obesity updates. Eli Lilly won the biggest plaudits...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?